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Summary. B-catenin expression in small cell lung 
carcinomas (SCLC) was investigated by immunohisto- 
chemical method using antibodies against B-catenin. 50 
pre-treatment biopsies were examined and the 
relationship between B-catenin expression and the 
patients' relevant clinical characteristics, response to 
chemotherapy, time to relapse or progression, and 
overall survival, were analyzed. 0-catenin expression 
exhibited different intensity within each sample, 
predominantly localized in the cytoplasm, and no sample 
showed nuclear expression. There was cytoplasmic 
hyperexpression in 14 cases, hypoexpression in 15 cases, 
and normal expression in 21 cases. We did not find any 
association between B-catenin expression and clinical 
data. Our results show, however, correlation between B- 
catenin cytoplasmic hyperexpression with a shorter time 
to progression (p=0.0437) as well as with a shorter 
overall survival @=0.0253). B-catenin hyperexpression 
could have prognostic significance in SCLC. 
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lntroductlon 
B-catenin is a multifunctional protein encoded in 
chromosome 3p21 (Nollet et al., 1996). One of the most 
important functions of this protein is cell-cell adhesion. 
B-catenin binds the intracytoplasmic domain of E- 
cadherin, the major adhesion molecule in epithelial 
tissues, and interacts with a-catenin, which binds the 
actin cytoskeleton (Shiozaki et al., 1996). This adhesion 
complex is essential in very many processes such as 
morphogenesis, control of cell motility during 
embryogenesis, maintenance of tissue integrity and 
control of contact-inhibition proliferation as well as 
being involved in the control of programmed cell-death 
(apoptosis) (Bullions and Levine, 1998). 
B-catenin is also able to bind cytoskeleton, 
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independently of the cadherin system, in two ways: B- 
catenin can bind actin filaments that link a protein called 
fascin, thereby helping to control cell motility (Tao et al., 
1996); and it can also interact with microtubules when 
they form a complex with a-catenin and the product of 
the adenomatous polyposis coli gene (APC) (Barth et al., 
1997). 
1n addition, D-catenin is involved in signal 
transduction by the WntIWingless growth factor; it 
activates gene transcription when it forms a complex 
with the DNA-binding proteins of the T-cell 
factorlLymphoid enhanced factor family (TcfnRf). The 
presence of a Wnt signal in normal cells stabilizes B- 
catenin, which accumulates in the cytoplasm, where it 
binds to Tcf/Lef factors, forming a complex that is 
translocated to the nucleus to trigger gene expression 
(Nakamura, 1997; Willert and Nusse, 1998; Bullions and 
Levine, 1998). 
The cytoplasmic leve1 of free B-catenin is low in 
normal cells because the protein is  targeted for 
destruction by APC protein, which is essential for the 
clearance of unneccesary B-catenin £rom the cytoplasm 
(Ilyas and Tomlinson, 1997). This homeostatic process 
may be altered by different mutations in APC (Korinek 
et al., 1997; Morin et al., 1997; Rubinfeld et al., 1997) or 
B-catenin (Ilyas et al., 1997; Fukuchi et al., 1998; Iwao 
et al., 1998; Palacios and Gamallo, 1998; Voeller et al., 
1998), that increase free B-catenin levels. Binding 
transcriptional factors, B-catenin increases the 
transcription of target genes that may increase cell 
proliferation or inhibit apoptosis. In this sense 8-catenin 
can act as an oncoprotein (Peifer, 1997; Hirohashi; 
1998). 
In surnmary, in normal cells í3-catenin is located in 
three cell compartments: the cell membrane where it acts 
in the cell-cell adhesion complex; in the cytoplasm 
where it acts in a free manner, and in the cell nuclei 
where it forms a complex with transcriptional factors 
(Stewart and Nelson, 1997; Papkoff, 1997). In the 
cytoplasm 8-catenin may form a complex with the 
product of the polyposis coli gene (APC) that induces B- 
catenin protein degradation. Other cytoplasmic proteins, 
such as axin or conductin, form different complexes with 
B-catenin and APC (Behrens et al., 1998). The glucogen- 
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synthetase kinase 38 (GSK-38) binds these three types of 
complexes, induces the phosphorylation in serine- 
threonin residues of APC and B-catenin and then leads 
the degradation of the protein by the ubiquitization 
process in the proteosomes (Aberle et al., 1997; Orford 
et al., 1997; Solomon et al., 1997). 
Since it was known B-catenin could act as an 
oncogen and could have an important role in the 
pathogenesis of some tumours, some studies were 
performed in severa1 neoplasms, but we did not find any 
studies of 0-catenin expression in small cell lung 
carcinomas (SCLC), the most aggressive type of lung 
cancer. In the present study, we examined B-catenin 
expression in 50 small cell lung carcinomas, and also 
assessed the association between this expression and 
clinical characteristics, response to treatment and 
survival. 
Materials and methods 
Patients 
We revised al1 patients with small cell lung 
carcinoma between 1990 and 1995 (a total of 163 
patients), and selected a total of 50 patients with 
histologically proven small cell lung carcinoma with 
biopsy tissue optimal to perform immunohistochemistry 
studies. Only those patients that underwent chemo- 
therapy treatment and with available evolutive data were 
selected. Patients were enrolled between January of 1990 
and December of 1995. The last follow-up was in 
December 1997 and al1 cases had a minimal follow-up 
of two years. Al1 received alternating chemotherapy with 
Cyclophosphamide, Doxorubicin and Vincristin, 
alternating with Cisplatin and Etoposide (CAVIPE 
schedule). No patient was lost to follow-up and no 
patient was alive after December 1997. 
Patients were considered to have limited disease if 
computed tomography (CT) scan of the chest and CT 
scan or ultrasound examination of the abdomen 
indicated that the tumour was confined to one 
hemithorax, to the mediastinal and supraclavicular 
lymph nodes, or there was an ipsilateral pleural efision. 
Otherwise, patients were considered to have extensive 
disease. The limited status of these patients' disease was 
also supported by the absence of metastases on a bone 
scan, a CT scan of the head, and a bone marrow biopsy. 
Response to treatment was considered to be 
complete if al1 disease found at the initial staging was 
absent as judged by imaging repeated at the completion 
of al1 treatments. A partial response was considered if 
imaging demonstrated at least 50% reduction in 
measurable tumor mass. Survival was calculated from 
the date of diagnosis to the date of death. 
Histological classification 
Specimens taken by bronchoscopy were routinely 
processed, fixed in 10% buffered formalin, embedded in 
parafin wax, sectioned at 4 pm,  and stained with 
haematoxylin and eosin. Al1 specimens were type 1 
SCLC in the MSLC (International Association for the 
Study of Lung Cancer) classification (Hirsh et al., 1988). 
Al1 samples were diagnosed and classified independently 
by two pathologists. 
lmmunohistochemistry 
Immunostaining was performed using the avidin- 
biotin-phosphatase-alkalin method. Briefly de- 
pa ra f f i ed ,  rehydrated sections were boiled in 10 mM 
citrate buffer @H 6) for 3 min in a pressure cooker to 
retrieve antigens. Excess citrate buffer was drained off, 
and sections were incubated at room temperature for 1 
hour with the anti-8-catenin mouse antibody (C19220, 
IgG 1 class, at 1:500 dilution, Transduction, United 
Kingdom). After being washed with Tris buffer, the 
secondary biotinylated antibody was added for 30 
minutes. Following the avidin-biotin complex 
(Vectastain ABC kit, Vector), slides were washed with 
Tris-buffer, and the Fast Red ITR chromogen procedure 
was performed. Finally, slides were counterstained with 
haematoxylin. The prirnary antibody was omitted or 
replaced by an irrelevant antibody in negative controls. 
Staining evaluation 
The CAS 200 Analyzer (Cell Analysis System, 
Lombard, IL) was used to quantitate B-catenin 
expression in tumour tissue and in adjacent normal 
respiratory epithelium. We created an index with these 
quantitative data: expression in tumour compared with 
expression in normal adjacent bronchial tissue in order 
to analyze the results. This index indicates how the 
expression in the tumour is deviated from that in normal 
tissue (Fig. 2). We considered B-catenin to be hypo- 
expressed if this index was lower than 1 (<0.70), when it 
was near 1 (0.70-1.30) we considered B-catenin to be 
normal or similar to the normal epithelium, and when it 
was much higher than 1 (>1.30) we considered B-catenin 
to be hyperexpressed. %o groups were created for the 
statistical analysis: one with B-catenin hyperexpressed 
and the other without hyperexpresion of B-catenin. 
Statistical methods 
The association between 0-catenin expression and 
biological or pathological variables (age, sex, 
performance status, weigh loss, stage, number of 
metastasis, response to treatment, time to progression 
and overall survival) was assessed using the chi-squared 
test with the Yates correction. The Fisher test was used 
to compare categorical data. Non-parametric Kruskall- 
Wallis one way analysis of variance was used to evaluate 
numerical data. The joint effect of .each presumedly 
prognostic variable was evaluated by multivariate 
analysis ubing a linear and a logistic-regression model. 
Significant was set at p<0.05. 
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Al1 analyses were conducted with the statistical 
packages Epi-Info 6.04a (Center for Disease Control and 
Prevention, USA) and SPSS 7.5 (Statistical Product and 
Service Solutions, Chicago, IL) for PC computers. 
Immunohistochemistry showed that al1 50 SCLC 
examined had B-catenin expression. This expression was 
heterogeneous and located in the cytoplasm 
with different intensity. We did not find 
nuclear expression in any sample. 
r .  We found that 21 cases had a global 
reduction of B-catenin expression (Fig. la), 
15 cases had normal expression (compared 
i with the protein expression in normal 
~ 
adjacent bronchial epithelium) (Fig. lb), and 
14 cases had a cytoplasmic hyper-expression 
of the protein (Fig. lc)  (index r 1.3). We 
grouped the 14 cases with B-catenin 
hyperexpression, and compared them to a 
group formed of patients with reduced 
expression and patients with conserved 
expression. We related these two groups 
with their clinical data and outcome. The 
results are shown in Table 1. 
Patient age, sex, performance status or 
weight loss were unrelated to B catenin 
expression. There was a tendency toward 
association between stage, number of 
I metastatic locations and type of chemotherapy response and B-catenin 
expression, but it was not satistically 
significant. Patients with increased 0-catenin 
accumulation had a tendency towards having 
extensive disease, more metastatic locations 
and fewer complete responses to treatment. 
The unívariate analysis showed a 
statistical association between B-catenin 
Results 
expression, time to progression and overall 
survival. These were shorter if B-catenin was 
hyperexpressed than if it was not, ranging 
154.552252.32 vs 210.872209.16 (p= 
0.0437), and 298.14+222.41 vs 417.162 
225.72 (p=0.0253), respectively (Figs. 2,3). 
Multivariant analysis was performed to 
analyze response to chemotherapy (logistic 
regression), overall survival (linear 
regression), and time to relapse (linear 
regression). B-catenin was not selected as an 
independent predictive factor of the 
dependent variable. The variables selected 
as predictive factors were stage and number 
of metastatic locations in the analysis of 
Flg. 1. Different beta-catenin expression patern in small cell 
lung carcinoma. a. Reducedlabsent beta-catenin expression 
(compare with normal epithelium at the center of the field). 
x 2.5. b. PreSe~ed beta-catenin expression (compare with 
normal epithelium at the top of the field). x 5. c. Beta-catenin 
hyperexpression. x 12.5 
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response to treatment; stage and type of chemotherapy 
response in the overall survival analysis; and finaily, in 
the multivariate analysis of time to relapse or 
progression, the most important predictive factor was 
stage (data not shown). 
Discussion 
This study demonstrates the presence of B-catenin 
expression in al1 the small cell lung carcinoma cases, 
independently of the intensity of the expression. This 
finding has an interesting potential for the differential 
diagnosis with the lymphoproliferative disorders in the 
lung, that do not express B-catenin, as was demonstrated 
by Takayama (Takayama et al., 1996,1998). 
The most interesting finding was the abnormal 
cytoplasmic hyperexpression of B-catenin in fourteen 
cases without nuclear expression. The only study on this 
tumor type that reports similar findings, is Nawrocki's 
recent report (Nawrocki et al., 1998). They studied B- 
catenin and E-cadherin expression in bronchopulmonary 
carcinomas, analyzing 44 samples resected from lung 
tumors, 4 of them being neuroendocrin tumors. These 
four samples showed cytoplasmic expression of B- 
catenin, one with faint intensity, one with moderate 
intensity, and two with strong intensity. The authors did 
not report any association with clinical data. 
Alteration of the B-catenin degradation system can 
promote an abnormal increase in the B-catenin 
cytoplasmic and nuclear pools. This fact has been 
demonstrated in vitro and in daerent neoplasms, such as 
ovarian (Palacios and Gamallo, 1998), endometrium 
(Fukuchi et al., 1998), prostate (Voeller et al., 1998) and 
colon carcinomas (Iwao et al., 1998). The alteration 
could be caused by different mechanisms: gene 
mutations (generally in exon 3 which alters the target of 
the GSK-3B phosphorylation sites) (Fukuchi et al., 1998; 
Iwao et al., 1998; Palacios and Gamallo, 1998; Voeiler et 
al., 1998) and mutations or inactivation of the APC 
function (Korinek et al., 1997; Morin et al., 1997; Peifer, 
1997; Rubinfeld et al., 1997), probably by the abnormal 
activation of Wnt signalling. It has been recently defined 
how the oncogenic activation of H-Ras oncogene can 
promote cytoplasmic and nuclear accumulation of B- 
catenin (Espada et al., 1999). The final result is a lower 
leve1 of 8-catenin degradation that could bind the 
TcfILef transcriptional factors, thereby forming a 
complex that is translocated to the nucleus and activates 
gene transcription. The results we observed in SCLC 
could not be explained by this process, as no sample had 
nuclear B-catenin. 
When B-catenin is located in the cell membrane, 
forming adhesion complexes with cadherins, it can be 
phosphorylated into tyrosin residues by different tyrosin- 
kinases such as membrane receptors (epidermal growth 
factor receptor, hepatocyte growth factor receptor) or the 
product of different oncogenes (c-erbB2, c-met, c-src, c- 
kit) (Daniel and Reynolds, 1997). This process 
Table 1. Clinical characteristics and 13-catenin expression. 
CHARACTERISTIC NO. OF PATIENTS (%) O-CATENIN EXPRESSION P VALUE 
Normal lncreased 
Sex 
Male 48 (96%) 34 
Female 2 (4%) 2 
Mean age I SD 61 18 61.2519.9 
ECOG 
0-2 47 34 
3-4 3 2 
Weigh los,% 
<5 25 20 
25 25 16 
Disease sfage 
Limited 21 (42%) 18 
Extensive 29 (56%) 18 
Number of metastasis 0:21 
1:14 
2:lO 
3:4 
4:2 
Response 
Complete m (40%) 16 4 0 . 1 F  
Qther 30 (60%) 20 10 
hfsan time to progression +SD 162121 O 21 0.8712Q9.1 154.551252.32 0.043* 
Mean overaii suMval *SD 3831228 41 7.1 61225.72 298.1 41222.41 0.025* 
SD: Standard Deviation; *: Fisher's exact test; *: Kruskall-Wallis non parametric test; *: Chi square and Yates correction. 
Mean: 1.1 4+0.8 
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disassembles the cell-cell adhesion complex and tyrosin- 
phosphorylated B-catenin remains in the cytoplasm. In 
normal tissues this process is reversible by the action of 
membrane tyrosin-phosphatases (Hirohashi, 1998). The 
dynamic regulation of cell adhesion aiiows the repair of 
tissues, as demonstrated in ulceration areas in gastric 
mucosa (Takeichi, 1993; Smith and Pignatelli, 1997; 
Muller et al., 1999). 
The  alteration of the B-catenin homeostatic 
mechanism could explain our results. The exclusive 
cytoplasmic accumulation of B-catenin could perhaps be 
the consequence of an abnomal tyrosin phosphorylation 
of the protein. v ros in  phosphorylation would be caused 
either by an abnormal activation of membrane receptors 
with tirosin-kinase activity, by hypofunction of the 
regulatory tyrosin-phosphatases, or by some regulatory 
mechanims, as yet unknown. Supporting this hypothesis, 
it has been demonstrated that different oncogenes with 
tyrosin-kinase activity, such as  c-kit and c-src, are 
frequently altered in SCLC (Kiefer et al., 1987; Hibi et 
al., 1991; Mellstrom et al., 1987; Sekido et al., 1991; 
Takeda et al., 1995; Krystal et al., 1996). 
Our results suggest that B-catenin could play an 
important role in the pathogenesis of SCLC related to a 
loss of cadherin-catenin cell adhesion function. This 
loss  is perhaps caused by an abnormal tyrosin- 
phosphorylation that disassembles the complex, giving 
the cell a more invasive and disseminative quality 
because of an increase in cell motility and loss of 
contact-inhibition growth. Further studies, which should 
be completed with an analysis of the phosphorylation 
status of the protein and of alteration in the c-kit and c- 
src genes may corroborate our hipothesis. 
These biological facts may help to explain the 
patients' clinical data and outcome. We found a tendency 
or marginal correlation between stage and the number of 
metastatic locations, they were larger in cases with 
hyperexpressed B-catenin. If further studies corroborate 
our hypothesis, B-catenin may possibly be a prognostic 
marker of tumoral dissemination. 
The finding of a correlation between time to relapse 
or progression after treatment and overall survival, 
which were shorter when there was  B-catenin 
hyperexpression, is important. Few studies relate B- 
catenin expression to patient outcome; only two of them, 
gastric (Jawhari e t  al., 1997) and oesophageal 
(Krishnadath et al., 1997) carcinomas, demonstrated that 
membrane hypoexpression of the protein was  an 
independent prognostic factor for survival. More 
extensive studies must be done to corroborate our 
findings. 
The multivariate analysis did not select B-catenin as 
an independent predictive factor for response, time to 
relapse or progression, or of overall survival. Our study 
could not perform a strong analysis of prognostic factors 
a s  the number of patients enrolled was  reduced. 
Additionally, the value of B-catenin cannot substitute the 
value of stage as predictive factor for patient outcome in 
SCLC (Garrido et al., 1994; Ihde et al., 1997). 
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